GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Enterprise Value

Redhill Biopharma (Redhill Biopharma) Enterprise Value : $10.26 Mil (As of May. 16, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Redhill Biopharma's Enterprise Value is $10.26 Mil. Redhill Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $47.13 Mil. Therefore, Redhill Biopharma's EV-to-EBIT ratio for today is 0.22.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Redhill Biopharma's Enterprise Value is $10.26 Mil. Redhill Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $111.71 Mil. Therefore, Redhill Biopharma's EV-to-EBITDA ratio for today is 0.09.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Redhill Biopharma's Enterprise Value is $10.26 Mil. Redhill Biopharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $35.75 Mil. Therefore, Redhill Biopharma's EV-to-Revenue ratio for today is 0.29.


Redhill Biopharma Enterprise Value Historical Data

The historical data trend for Redhill Biopharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Enterprise Value Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 170.03 367.37 185.00 115.78 24.33

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 137.80 115.78 0.47 - 24.33

Competitive Comparison of Redhill Biopharma's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Enterprise Value falls into.



Redhill Biopharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Redhill Biopharma's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Redhill Biopharma's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (NAS:RDHL) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Redhill Biopharma's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10.263/47.129
=0.22

Redhill Biopharma's current Enterprise Value is $10.26 Mil.
Redhill Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.13 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Redhill Biopharma's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=10.263/111.714
=0.09

Redhill Biopharma's current Enterprise Value is $10.26 Mil.
Redhill Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $111.71 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Redhill Biopharma's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10.263/35.745
=0.29

Redhill Biopharma's current Enterprise Value is $10.26 Mil.
Redhill Biopharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.